New York, October 15th / PRNewswire / -- Pomerantz LLP represents and stands for Rafael Holdings, Inc. ("Rafael" or "the company") ( NYSE : RFL ). The firm advises relevant investors to contact Danielle Peyton, whose email is [ email protected ], the phone number is 646-581-9980, extension 7980.
This investigation involves whether Rafael and some of its senior executives and/or directors are engaged in securities fraud or other illegal business practices.
[Click here to learn about joining the class action.]
On September 30, Rafael issued a press release announcing that its subsidiaries Cyclo Therapeutics and LLC conducted a pivotal Phase 3 TransportNPC study ( CTD-TCNPC-301 ) in which the top-line efficacy and safety data of Trappsol Cyclo ™ (intravenous hydroxypropyl-β-cyclodextrin) were evaluated in 94 patients diagnosed with Niemann-Pick disease type C ( NPC ). The press release stated, "The results did not achieve statistical significance on the primary endpoint."
Affected by this news, the stock price of Rafael fell by $0.71, or 34.98%, to close at $1.32 per share on September 30, 2026.
Pomerantz LLP has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and is recognized as one of the leading law firms in the fields of corporate law, securities law, and class action litigation. The firm was founded by the late Abraham L Pomerantz, who is known as the "dean" of the class action litigation community and pioneered the field of securities class actions. More than 85 years have passed since then, and Pomerantz continues this tradition, working to protect the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has secured millions of dollars in compensation for its class members. For more information, please visit www.pomlaw.com.
Lawyer advertisement. Past results do not guarantee similar outcomes.
Contact Information:
Danielle PeytonPomerantz LLP[ email protected ]646-581-9980 ext . 7980
